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Summary
The mechanisms that regulate mammalian organ size
are poorly understood. It is unclear whether the path-
ways that control organ size also impinge on stem/pro-
genitor cells. A highly expressed gene in stem cells is
YAP1 [1], the ortholog of Drosophila Yorkie, a down-
streamcomponent of theHippo pathway [2]. Mutations
in components of this pathway produce tissue over-
growth phenotypes in the fly whereas mammalian
orthologs, like salvador [3], merlin [4], LATS [5], and
YAP1 [6, 7], have been implicated in tumorigenesis.We
report here that YAP1 increases organ size and causes
aberrant tissue expansion in mice. YAP1 activation
reversibly increases liver size more than 4-fold. In the
intestine, expression of endogenousYAP1 is restricted
to theprogenitor/stemcell compartment,andactivation
of YAP1 expandsmultipotent undifferentiated progeni-
tor cells, which differentiate upon cessation of YAP1
expression. YAP1 stimulates Notch signaling, and ad-
ministration of g-secretase inhibitors suppressed the
intestinal dysplasia causedbyYAP1. Humancolorectal
cancers expressing higher levels of YAP1 sharemolec-
ular aspects with YAP1-induced dysplastic growth in
the mouse. Our data show that the Hippo signaling
pathway regulates organ size in mammals and can
act on stem cell compartments, indicating a potential
link between stem/progenitor cells, organ size, and
cancer.
Results and Discussion
YAP1 Regulates Organ Size in a Reversible Manner
To study whether the Hippo pathway regulates organ
size in mammals, we generated transgenic mice in which
YAP1 could be activated in a doxycycline (Dox)-induc-
ible manner. We chose to study the effect of YAP1 activa-
tion in the liver because mammals tolerate large changes
in liver size [8]. By using site-specific recombination in
embryonic stem (ES) cells, a doxycycline-dependent
allele of YAP1 was targeted downstream of the collagen
1a1 locus by site-specific integration (TetO-YAP1) [9]. A
mutated version of YAP1 was used containing a S127A
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increases the nuclear localization and transcriptional ac-
tivity of YAP1 because it escapes 14-3-3-mediated inhi-
bition [10]. TetO-YAP1 transgenic mice were crossed
with mice expressing the tetracycline transactivator
(tTA) under control of the liver activator protein (LAP) pro-
moter (Figure 1A) [11]. YAP1 is expressed at very low
levels in adult hepatocytes (data not shown), and as ex-
pected, withdrawal of doxycycline in double transgenic
LAP1-YAP1 mice induced robust levels of YAP1 protein
as compared to littermate controls (Figure 1D).
Activation of YAP1 for 35 days in adult mice resulted
in a more than 4-fold (4.13) increase in liver size (Fig-
ure 1B). Microscopic analysis of the liver revealed dys-
plastic hepatocytes with irregular, enlarged nuclei, a
high nuclear to cytoplasmic ratio (Figure 1C), and in-
creased proliferation as indicated by increased mitotic
figures and Ki-67-positive cells throughout the liver (Fig-
ure 1E) and increased PCNA levels (Figure 1D). Because
activation of Drosophila Yorkie inhibits apoptosis [2],
we asked whether YAP1 would also protect against cell
death. Efficient apoptosis was induced in the liver by
the injection of a monoclonal Fas antibody [12] in wild-
type mice (Figures S1A and S1B in the Supplemental
Data available online). In animals expressing YAP1 for 4
days, however, hepatocytes were largely unresponsive
to Fas-mediated apoptosis (Figures S1A and S1B).
Furthermore, the cells in the enlarged liver still express
liver albumin, indicating their differentiated nature (Fig-
ure S1C). Consistent with studies in Drosophila, activa-
tion of the Hippo pathway expands organ size by in-
creasing cell number rather than cell size, indicated by
an increase in the number of nuclei per microscopic field
in the enlarged liver (Figure S1D). Interestingly, the in-
crease in liver mass was completely reversible, as indi-
cated by the fact that interruption of YAP1 expression
for 5 weeks resulted in a normally sized liver without
any gross abnormalities (Figure 1B). These results pro-
vide evidence that activation of a key component of the
mammalian Hippo pathway leads to tissue expansion
and increased organ size.
YAP1 Is Expressed in the Stem Cell Compartment
of the Intestine
In contrast to the liver, many organs largely consist of
terminally differentiated cells that are unable to resume
proliferation. In these tissues, renewal and repair relies
on specialized stem cells resident in defined progenitor
cell compartments. One example of such organ is the
intestine, where endogenous YAP1 is expressed in the
crypt compartment, where the stem/progenitor cells re-
side (Figure 1F). Expansions of cells that have an undif-
ferentiated crypt/progenitor phenotype, such as APCmin
adenomas, also express high levels of YAP1 (Figure 1F).
These results are in agreement with and extend previous
findings describing Yap1 as a ‘‘stemness gene’’ based
on its expression pattern [1].
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2055Figure 1. Tissue Expansion upon YAP1 Activation in the Liver
(A) Schematic representation of liver-specific doxycycline-inducible YAP1 allele. The tetracycline transactivator (tTA) expression is driven by the
liver activator protein (LAP) promoter. A tetracycline regulatable allele of YAP1-S127A was integrated downstream of the Col1A1 locus.
(B) Gross morphology of the liver in control and YAP1 transgenic mice induced for 5 weeks (top) and mice induced for 5 weeks followed by
reversal of YAP1 activation for another 5 weeks (bottom).
(C) Hematoxylin and eosin (H&E)-stained sections of liver from control and YAP1 mice induced for 5 weeks.
(D) Expression of PCNA and YAP1 protein in the liver of control and transgenic mice after 4 days of induction.
(E) Ki-67 stains of control and YAP1-expressing livers indicate enhanced hepatocyte proliferation as a consequence of YAP1 activation.
(F) Immunohistochemical detection of YAP1 expression in the crypt compartment of the small intestine and in APCmin adenomas.YAP1 Induces Intestinal Dysplasia that Lacks
Differentiated Cell Types
To study the effects of YAP1 activation in the intestine
and in other organs, we generated mice containing a
doxycycline-dependent reverse transactivator recom-
bined into the ubiquitously active ROSA26 (R26) locus
in addition to the TetO-YAP1 allele [9]. Upon activation
of YAP1 in chimeric mice carrying these transgenes,
the pancreata increased in total size and acinar cells
revealed a fully penetrant ductal metaplasia in some re-
gions (Figure S2A). This is reminiscent of the phenotype
observed in mice lacking expression of PTEN in the pan-
creas [13] where the neoplasia originates from Hes1-
postitive centroacinar cells, a candidate progenitor cell
of the pancreas [14]. We found that the ductal metaplasiaof the pancreatic acinar cells caused by the activation
of YAP1 also expresses Hes1 (Figure S2A), suggesting
that these lesions are caused by expansion of potential
pancreatic progenitor cells.
Fully transgenic mice became ill after 3 days of induc-
tion and had to be euthanized by 4–6 days. Although sev-
eral tissues were affected by YAP1, such as the skin,
which displayed a thickening of the epidermis and an
increase in the number of proliferating cells (Figure S2B),
the most dramatic phenotype observed in these mice
was a severe dysplasia located along the entire intestinal
epithelium (Figure 2A). Proliferation was greatly in-
creased upon YAP1 activation (Figure 2A), consistent
with increased PCNA protein levels (Figure 2C). In con-
trast to control mice, proliferation upon YAP1 activation
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2056Figure 2. YAP1-Induced Loss of Differentiation and Expansion of Progenitor Cells in the Small Intestine
(A) H&E-stained sections of control and R26-YAP1 mice 5 days after induction. High-magnification insets indicate tissue dysplasia. Dysplastic
regions stain positive for YAP1. Ki-67 staining indicates expansion of proliferative progenitor compartment. Alkaline phosphatase (AP) staining
indicates loss of differentiated enterocytes upon YAP1 induction, and periodic acid-Schiff (PAS) staining indicates absence of goblet cell differ-
entiation. Staining for Hes-1 is normally restricted to progenitor cells in the crypt region. Note that this antibody is known to unspecifically stain
goblet cells as seen in control mouse (13). YAP1-induced dysplasia stains positive for Hes1 along the entire epithelial cell layer.
(B) Transmission EM analysis of the apical surface of intestinal epithelial cells reveals short, thick, and nonuniform microvilli after YAP1 induction
for 4 days, typical of brush border of undifferentiated cells.
(C) Immunoblot analysis of R26-YAP1 embryonic stem cells and transgenic mouse small intestine for YAP1, PCNA, and actin after 2 and 5 days,
respectively, of doxycyline induction of YAP1.was not restricted to the crypt regions but was also de-
tected at the villus regions and at the tip of the villi (Fig-
ure 2A). When analyzed for alkaline phosphatase activity,
amarkerofdifferentiated enterocytes, wenoticed acom-
plete absence of staining in the small intestine 5 daysafter doxycycline induction (Figure 2A). Mature goblet
cells and Paneth cells were also absent 5 days after
YAP1 activation (Figure 2A). These results indicated that
activation of YAP1 leads to a loss of differentiated cell
types in the small intestine.
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2057Figure 3. YAP1 Activation Rapidly and Reversibly Expands Undifferentiated Progenitor Cells
Time course of doxycycline-induced dysplasia by H&E stain, alkaline phosphatase (AP) staining for differentiated enterocytes, and PAS staining,
indicating differentiated goblet cells.YAP1 Reversibly Expands Undifferentiated
Progenitor Cells
An explanation for the complete absence of differenti-
ated cells in the intestinal epithelium of R26-YAP1 trans-
genic mice could be dedifferentiation of mature cells or
expansion of an undifferentiated population. In order to
address these possibilities, we analyzed the small intes-
tine of transgenic mice after 2.5 days of YAP1 induction.
Staining with alkaline phosphatase and PAS revealed
that the few remaining differentiated cells were found
exclusively at the tip of the villi (Figure 3). This result
argues against dedifferentiation and suggests that, upon
YAP1 activation, undifferentiated cells derived from the
crypt expand and replace mature cell types. Hes1, a
Notch target gene, is normally expressed only by the
undifferentiated crypt progenitor cell population [15].
However, after YAP1 activation, the Hes1-expressing
cell compartment was expanded to include all epithelial
cells along the villi (Figure 2A). In addition, transmission
EM analysis of the apical surface of YAP1 intestinal
epithelial cells revealed short and thick nonuniform mi-
crovilli (Figure 2B) resembling the brush border of undif-
ferentiated crypt cells [16]. We next tested whether
this block in differentiation required continuous YAP1
expression. Mice were induced with doxycycline for
4.5 days and withdrawn for 2 extra days. As shown in
Figure 3, inactivation of YAP1 leads to the rapid reap-
pearance of differentiated enterocytes, goblet cells,
and Paneth cells. Although a very similar phenotype is
seen in mice upon activation of the OCT4 [17], the ex-
pansion of undifferentiated cells by YAP1 is indepen-
dent of OCT4, as shown by the fact that the dysplastic
tissue in the intestine does not detectably expressOCT4 and YAP1 does not seem to regulate OCT4 levels
in ES cells (Figure S3). Altogether, these data suggest
that activation of YAP1 results in the expansion of multi-
potent undifferentiated intestinal progenitor cells that
retain the ability to resume differentiation upon interrup-
tion of YAP1 expression.
Effects of YAP1 on WNT Signaling
WNT signaling is important for the maintenance and ex-
pansion of undifferentiated progenitor cells in the small
intestine [18]. Interestingly, in Drosophila, Yorkie activa-
tion leads to expansion of cells that express Wingless,
the fly homolog of the mammalianwnt genes [19]. YAP1-
induced intestinal dysplasias expressed increased
amounts of nuclear b-catenin, indicative of WNT pathway
activation (FigureS4A).Target genes of theWNTpathway
in the intestine include the EphB2 and EphB3 receptors,
which are involved in correctly positioning Paneth cells
at the bottom of the crypt [20]. Activation of YAP1 for 4
days resulted in an expansion of the EphB2-positive
compartment (Figure S4B). The functional consequence
of altered WNT signaling became evident shortly after
YAP1 activation (2.5 days) when Paneth cells lost their
position and could now be observed higher up in the villi
(Figure S4C). Such phenotype has been described upon
loss of the APC tumor suppressor gene in the mouse
intestine [21, 22].
Prevention of YAP1 Induced Dysplasia
by g-Secretase Inhibitors
Notch signaling is also important for the maintenance of
undifferentiated progenitor/stem cells in the small intes-
tine [23]. The Notch signaling pathway is stimulated
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2058Figure 4. Suppression of YAP1-Induced Dysplasia by g-Secretase Inhibitors and Expression Analysis of YAP1 in Human Colorectal Cancer
(A) Activation of YAP1 rapidly leads to Hes-1 induction, indicative of Notch signaling. Note the upregulation of Hes1 in nondysplastic, differen-
tiated, AP-positive enterocytes.
(B) Mice of the noted genotypes were induced with doxycycline for 4.5 days in the absence or presence of 16 mmol/kg daily-injected dipenza-
zepine (DBZ, g-secretase inhibitor), and sections were stained for Ki-67, periodic acid-Schiff (PAS), and Alkaline phosphatase (AP) to detect
proliferating cells, goblet cells, and differentiated enterocytes, respectively.
(C) Expression profiles of 105 different human colon cancers were analyzed to identify genes that were coexpressed with YAP1 in colon cancer.
Clustering analysis reveals that those tumors that express relatively high levels of YAP1 also show high expression levels of both BclXL and
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comes fully dysplastic and undifferentiated. This is indi-
cated by the activation of HES1 expression in cells that
contain a fully differentiated brush border shown by al-
kaline phosphatase staining 2.5 days after YAP1 activa-
tion (Figure 4A). Also in Drosophila, Yorkie-expressing
clones display increased levels of the Notch ligand
Serrate [19]. To test whether blocking of the Notch cas-
cade could suppress the dysplasia caused by YAP1, we
treated mice with g-secretase inhibitors during YAP1 ac-
tivation [24]. Treatment of control animals with dipenza-
zepine (DBZ) leads to a significant increase in goblet cell
numbers (Figure 4B), as described previously [25]. YAP1
induction in the presence of g-secretase inhibitors led to
a much less dysplastic phenotype in the intestine, indi-
cated by a decrease in proliferation and the presence
of goblet cells and differentiated enterocytes (Figure 4B).
Although these results do not rule out the possibility that
g-secretase inhibitors suppress YAP1-induced pheno-
types through biological processes other than Notch
signaling, they are consistent with a model in which
YAP1-mediated expansion of intestinal progenitor cells
at least partially relies on activation of the Notch signal-
ing pathway.
Similarity of YAP1-Induced Dysplasia with Human
Colon Cancers
All components of the Drosophila Hippo signaling path-
way are conserved in vertebrates and many have been
implicated in cancer [26]. We therefore wanted to deter-
mine whether YAP1-induced dysplasia in the mouse
shows any similarity to human tumors that express
high levels of YAP1. Activation of YAP1 in mice leads
to dysplasia in the intestine, so we analyzed YAP1 ex-
pression in a publicly available data set of microarray
gene expression data of a panel of 105 human colorectal
cancers. Interestingly, YAP1 expression levels were strik-
ingly correlated with the expression levels of both cy-
clinD1 and BclXL (Figure 4C), genes that are also highly
expressed in YAP1 transgenic intestinal dysplasias
(Figure 4D). This may be caused by a relative increase
of progenitor cells rather than a direct consequence of
YAP1 activation because activation of YAP1 in ES cells
does not elevate the levels of BclXL or cyclin D1
(Figure 4D). The similar expression of high levels of cy-
clin D1 and BclXL suggests that the activation of YAP1
in the mouse intestine activates a biological state that
is similarly present in a subset of human colorectal tu-
mors that express higher levels of YAP1. Whether the
tumors that express high levels of YAP1 will be sensitive
to treatment with g-secretase inhibitors warrants further
investigation.
Not much is known on how the growth of organs is
regulated, controlled, and stopped when a tissue has
reached its correct size. In Drosophila, the Hippo path-
way has emerged as an important regulator of tissue
size [26]. Here we show that the Hippo signaling compo-
nent YAP1 regulates organ size in mammals. Severalaspects of size control at the organ level differ from
growth control at the level of the organism. For instance,
in an adult mouse, deregulation of YAP1 in the liver can
drastically increase organ size. Growth of a mammalian
organism, on the other hand, is for the most part irre-
versible and the final size an organism reaches can be
affected only during development. In contrast to the
growth of an organism, this form of (over)-growth ap-
pears to be completely reversible, indicating that the
liver ‘‘has remembered’’ its correct size and knows ex-
actly when to discontinue shrinking. Such responsive-
ness to YAP1 activation in adulthood is not restricted
to the liver, an organ that is known for its ability to grow
and regenerate in adulthood, but besides the liver a vari-
ety of other tissues also respond to YAP1 activation,
such as intestine and skin.
Similar to the WNT signaling pathway (activated by
loss of the APC tumor suppressor gene [22]) or OCT4
[17], YAP1 is able to drive expansion of undifferentiated
progenitor cells in the intestine. From a developmental
perspective, this could originate from the logical re-
quirement to synchronize stem cell numbers and organ
size during development. Pathways that regulate the ex-
pansion of stem cells, such as the WNT and Hedgehog
signaling pathways, are frequently mutated in human
cancer. Indeed, it is possible that Hippo pathway dereg-
ulation also contributes to tumor development by stim-
ulating the accumulation of undifferentiated progenitor/
stem cells. Further elucidation of the signals that acti-
vate the Hippo pathway and the transcription factors
downstream of YAP1 will be needed for a more com-
plete understanding on how the Hippo pathway controls
tissue size.
Supplemental Data
Four figures and Experimental Procedures are available at http://
www.current-biology.com/cgi/content/full/17/23/2054/DC1/.
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Note Added in Proof
While this manuscript was under revision, another group reported
observations similar to those presented in Figure 1B and Figure
S1. The following is the complete reference listing for that study:
Dong, J., Feldmann, G., Huang, J., Wu, S., Zhang, N., Comerford,
S.A., Gayyed, M.F., Anders, R.A., Maitra, A., and Pan, D. (2007). Elu-
cidation of a universal size-control mechanism in Drosophila and
mammals. Cell 130, 1120–1133.
